News Center

With the tenet of "Healthy China, Dedicated commitment", Linuo Pharmaceuticals increases cooperation and association with external scientific research institutes while innovating and developing independently.

Corporate News

Staff Style

Home page

Great news! First prize!

Recently, the Jinan Municipal Federation of Trade Unions officially announced the list of winners for the 2025 “Making Contributions in the Spring City” Innovation and Excellence Labor Competition. Shandong Linuo Pharmaceutical Co., Ltd.’s Solid Dosage Form Workshop stood out among numerous outstanding work teams across the city thanks to its remarkable performance, rigorous work style, and exceptional innovative capabilities, earning the prestigious First Prize for Work Teams.

2026

Deepening Government-Enterprise Cooperation: Yi’nan County Party Secretary Hou Zhanfu and Delegation Conduct Research Visit to Keyuan Pharmaceutical and Linuo Pharmaceutical

On April 27, Hou Zhanfu, Secretary of the Yinan County Party Committee, and Ren Lijun, a member of the County Government Party Leadership Group and Deputy County Magistrate, led a delegation comprising heads of the County Health Commission, the County Bureau of Industry and Information Technology, the County Finance and Investment Group, and other relevant departments on a field visit to Keyuan Pharmaceutical and Linuo Pharmaceutical to assess the companies’ development status and discuss ways to deepen government–enterprise cooperation and promote high-quality development of the pharmaceutical and health industries.

2026

Tracing the Footsteps of Mountains, Waters, and Sages While Exploring New Growth Opportunities in the Pharmaceutical Industry — Industry Leaders Gather in the “Spring City,” as Keyyuan Pharmaceutical’s Subsidiary Unveils Several Major New Products

From April 24 to 27, the themed event “Tracing the Footsteps of a Mountain, a River, and a Sage; Exploring the Origins of a Gold Award and a Renowned Institution” was successfully held in Jinan.

2026

Powerful Partnership, Ushering in a New Journey: Linuo Pharmaceutical and Hubei General Pharmaceutical Co., Ltd. Sign a Strategic Cooperation Agreement

On April 21, Shandong Linuo Pharmaceutical Co., Ltd., a wholly owned subsidiary of Shandong Keyuan Pharmaceutical Co., Ltd. (stock code: 301281.SZ), and Hubei General Pharmaceutical Co., Ltd. held a grand signing ceremony for a strategic cooperation agreement. The two companies, leveraging their respective strengths and complementing each other’s advantages, will deepen comprehensive collaboration in areas such as product distribution, supply-chain synergy, and coverage of medical end-users, thereby pooling resources to support the “Healthy China” initiative and jointly forge a new paradigm for high-quality development of the pharmaceutical industry.

2026

Good News! Seven products from Linuo Pharmaceutical are slated to win bids in the national centralized procurement continuation project!

Recently, the bidding process for the new round of follow-up procurement of drugs under the national centralized procurement programs from batches 1 to 8 has concluded, yielding preliminary winning results. This round of follow-up procurement was jointly organized by the National Healthcare Security Administration, with Jiangsu, Henan, and Guangdong provinces serving as joint lead agencies, and was implemented nationwide in a coordinated manner. It achieved “three unifications”—unified procurement rules, standardized operational procedures, and a consistent market scope—marking an important milestone in deepening and systematizing the centralized procurement reform.

2026

[Building a Learning-Oriented Team—Lesson 19] Learn the New Regulations, Uphold Compliance! Linuo Pharmaceutical Conducts Special Training on the Implementation Regulations of the Drug Administration Law!

Drug safety is closely linked to people’s health, and the rule of law provides a solid framework to support the development of the pharmaceutical industry. On January 27, the newly revised “Implementation Regulations of the Drug Administration Law of the People’s Republic of China” (hereinafter referred to as the “Regulations”) were officially promulgated. These Regulations strengthen the legal framework for drug safety, refine regulatory requirements, and establish clear guidelines for the full lifecycle management of drugs—from research and development to production, distribution, and use—directly impacting enterprises’ compliance operations and high-quality development.

2026

< 1 2 3 4...21 >

TEL：+86-531-88729642

E-mail：lnyybgs@lnphar.com

ADD：#30766 Jingshidong Road, Linuo High-tech Park, Jinan, Shandong Province, P. R. China